News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Viamet Pharmaceuticals and the National Institutes of Health (NIH) to Jointly Develop Novel Viamet Compound


7/28/2011 8:44:27 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc. announced today that one of its novel antifungal compounds has been selected for inclusion in the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program. TRND is a government-funded program specifically designed to speed development of new therapies for rare and neglected diseases. Together, Viamet and NIH will pursue development of Viamet’s oral antifungal agent for the treatment of cryptococcal meningitis, a life-threatening fungal infection which annually afflicts over 1 million people in the developing world, resulting in approximately 500,000 deaths.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES